MedTrace Logo

Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19

NCT04420247 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2021-05-12

No results posted yet for this study

Summary

Facing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro antiviral role proven by numerous studies and with a well defined safety profile established, for efficacy in treating COVID-19 and improving an ordinal primary outcome composed by a 9-levels scale, which was recomended by the World Health Organization.

Conditions

Interventions

DRUG

Chloroquine

5 days of treatment with Chloroquine + Standard Care

DRUG

Hydroxychloroquine

5 days of treatment with Hydroxychloroquine + Standard Care

OTHER

standard care

Standard Care according to Brazilian Guidelines for treating COVID-19

Sponsors & Collaborators

  • Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2020-08-20
Completion
2020-09-03

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420247 on ClinicalTrials.gov